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tporter@uky.eduAbstract Cytochrome P450 reductase (POR) is an essential electron transfer protein located on
the endoplasmic reticulum of most cell types, and has long been appreciated for its role in
cytochrome P450-mediated drug metabolism. Additional roles and electron acceptors for POR
have been described, but it is largely with the recent availability of POR-null tissues that these
supplemental roles for POR have been able to be explored. These studies have conﬁrmed POR as
the principal redox partner for the microsomal P450s responsible for drug and xenobiotic
metabolism as well as cholesterol and bile acid synthesis, and for heme oxygenase, which catalyzes
the initial step in the breakdown of heme. Surprisingly, these studies have revealed that squalene
monooxygenase, an enzyme essential to cholesterol synthesis, has a second unknown redox partner
in addition to POR, and that 7-dehydrocholesterol reductase, previously proposed to require POR
as an electron donor, functions fully independently of POR. These studies have also helped deﬁne
the role of cytochrome b5 in P450 catalysis, and raise the question as to the extent to which POR
contributes to b5-dependent redox pathways.
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New insights into the role of cytochrome P450 reductase 1031. Early identiﬁcation of redox partners for cytochrome
P450 reductase
The early history of cytochrome P450 reductase (POR) is
described in a comprehensive review by Masters and Okita1.
Cytochrome P450 reductase was initially identiﬁed as a
TPNH(NADPH)-dependent cytochrome c reductase present
in liver extracts, but subsequent studies demonstrated that
cytochrome c, a mitochondrial protein, was not this micro-
somal enzyme’s natural redox partner. The redox partner for
POR remained unknown for over a decade, until the early
1960s when it was suggested that POR might be involved in
drug and steroid oxidations by the newly discovered cyto-
chrome P450 system. The observation that POR activity was
inducible by drugs that increased microsomal P450 expression
was undertaken. These studies have greatly facilitated by
antibody inhibition studies that clearly showed that antibody
to POR inhibited microsomal drug oxidations. The reconsti-
tution of cytochrome P450 activity by Lu and Coon in 19682
from solubilized components, including a POR-containing
fraction, established P450 as the ﬁrst redox partner for POR.
Antibody inhibition studies were used to identify additional
redox partners for POR, and led to the identiﬁcation of heme
oxygenase3, a microsomal enzyme that catalyzes the ﬁrst step
in heme degradation. Antibody inhibition was also used to
show that steroid hydroxylations in the adrenal cortex4,
placenta5, and testis6 were dependent on POR, thus expanding
the range of P450s that serve as POR partners to those
involved in physiological biochemistry as well as drug and
xenobiotic metabolism. Squalene monooxygenase (epoxidase)
was identiﬁed as a redox partner for POR in 19777, making it
the second non-P450 enzyme, after heme oxygenase, to use
POR as an electron source; squalene monooxygenase acts in
the cholesterol synthesis pathway. The ability of POR to
donate electrons to cytochrome b5
8 generated considerable
interest as to the relevance of this pathway to P450 function,
as b5 was able to donate the second of the two required
electrons to cytochrome P450 in isolated and reconstituted
preparations. Moreover, cytochrome b5 is part of the fatty
acid desaturation and elongation pathways as well as the post-
lanosterol sterol synthesis pathway, placing POR at the inter-
face of drug and xenobiotic metabolism, steroid and choles-
terol synthesis, and fatty acid metabolism. The last enzyme to
be associated with POR is 7-dehydrocholesterol reductase,
which catalyzes the ﬁnal step in cholesterol synthesis; muta-
tions in the gene for 7-dehydrocholesterol reductase are
responsible for Smith-Lemli-Opitz syndrome9. Antibody inhi-
bition studies again implicated POR as an electron donor to
this enzyme, an idea further supported by reconstitution
studies with partially puriﬁed enzyme preparations10. How-
ever, very recent studies from the author’s laboratory have
demonstrated that POR does not have a role in 7-dehydro-
cholesterol reductase function11.2. Studies with hepatic POR-null mice
The germline deletion of POR in mice results in embryonic
lethality by day 1412, making whole-animal knock-out studies
unfeasible. The lethality appears due to the loss of cholesterol
synthesis necessary for neuronal development and to the
loss of sterol modiﬁcation of proteins necessary fordevelopment13,14. To circumvent this problem the selective,
tissue-speciﬁc deletion of POR expression was undertaken.
These studies have greatly facilitated studies on the role of
POR in drug metabolism, tissue and organ-speciﬁc toxicity of
xenobiotics, and organismal development15,16.
2.1. Heme oxygenase
In one of the two seminal studies on hepatic POR-null mice,
Gu et al.15 noted that the inducible form of heme oxygenase,
HO-1, was induced 9-fold at the protein level in the livers of
these mice, and yet heme oxygenase activity was essentially
negligible in this tissue. The Wolf laboratory did not look at
heme oxygenase protein or activity in their hepatic POR-null
mice, but did note a modest increase (1.4 to 2-fold) in
HO-1 mRNA levels in POR-null liver17. A microarray study
from the Ding laboratory similarly found a 2.3-fold increase in
HO-1 mRNA18. The expression of heme oxygenase-2, a con-
stitutively expressed form present in normal liver, was not
altered at the mRNA or protein level by the loss of POR
expression. The lack of heme oxygenase activity in POR-null
liver in the face of a signiﬁcant increase in protein argues
strongly that POR is the requisite and only electron transfer
partner for this enzyme. Although there was some evidence for
oxidative stress in the livers of these animals (evidenced by an
increase in glutathione-S-transferase gene expression)18 con-
sistent with the increase in HO-1 expression, no direct
evidence of heme toxicity was noted. Biliverdin and bilirubin
levels were not measured in the livers or blood of these
animals and the question of how heme turnover is handled
in a hepatic POR-null liver remains to be determined.
2.2. Squalene monooxygenase
Squalene monooxygenase catalyzes the ﬁrst oxidative step in
the synthesis of sterols, yielding 2,3-oxidosqualene which is
then cyclized by 2,3-oxidosqualene cyclase to the ﬁrst sterol in
the pathway, lanosterol. Squalene monooxygenase is an FAD-
dependent monooxygenase which is unusual in its requirement
for an additional electron transfer partner. Early puriﬁcation
studies demonstrated that activity could be reconstituted with
POR7, and it was not until hepatic POR-null microsomes
became available that it could be shown that squalene
monooxygenase retained partial activity in the absence of
POR19. The second microsomal reductase, still unidentiﬁed,
appears able to catalyze approximately 40% of the activity
seen in POR-containing liver microsomes. Sterol analysis of
the livers of hepatic POR-null mice revealed elevated levels of
dihydrolanosterol, a metabolite of lanosterol formed by sterol
24-reductase, a downstream enzyme in cholesterol synthesis.
This metabolite also accumulated in hepatocytes isolated from
hepatic POR-null mice, demonstrating that squalene is con-
verted to lanosterol via squalene monooxygenase and 2,3-
oxidosqualene cyclase in the absence of POR. Studies with rat
hepatoma cells in which POR expression is suppressed by
RNA interference (RNAi) similarly demonstrated the accu-
mulation of lanosterol and dihydrolanosterol20, conﬁrming
that squalene monooxygenase activity was resilient to the loss
of POR. Notably, sterol synthesis is blocked at lanosterol
demethylase, resulting in the accumulation of lanosterol and
dihydrolanosterol; lanosterol demethylase is a cytochrome
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activity. Squalene monooxygenase protein levels are decreased
by approximately 40% in POR-null liver despite a two-fold
increase in mRNA levels. While this suggests that lanosterol
or its metabolite act post-transcriptionally to decrease squa-
lene monooxygenase expression (as is seen with HMG-CoA
reductase21), Gill et al.22, have recently shown that the turn-
over of squalene monooxygenase is accelerated by cholesterol
but not by lanosterol or dihydrolanosterol. In hepatic POR-
null cells the inability to convert cholesterol to bile acids (a
P450-dependent reaction) may result in the accumulation of
sufﬁcient cholesterol to promote the degradation of squalene
monooxygenase, although cholesterol levels in these cells are
not noticeably elevated (unpublished data).
Interestingly, the sterol synthesis pathway in Saccharo-
myces cerevisiae, which yields ergosterol, is not dependent
on POR23 despite the involvement of two P450s (CYP51 and
CYP61), as well as squalene monooxygenase. The assumption
is that the NADH-cytochrome b5 pathway supports CYP51
and CYP61 in yeast, but S. cerevisiae squalene monooxygen-
ase activity cannot be supported by NADH in microsomes24,
raising the possibility that that this yeast, like mammals,
contains a second reductase capable of reducing squalene
monooxygenase.2.3. Cytochrome b5
The earliest studies on the P450 system indicated a role for
cytochrome b5 in this pathway, but establishing the speciﬁcs of
the interaction was contentious. Cytochrome b5 is reduced by
NADH via cytochrome b5 reductase, and there was good
evidence that this NADH-dependent pathway could support
modest P450 activity in microsomal preparations25. Later
reconstitution studies with puriﬁed enzymes supported this
observation for some, but not all P450 isoforms26,27, as did
recombinant expression studies28. Nonetheless, the ability of
POR to transfer electronsto b5
8 complicates the picture, and
the ability of cytochrome b5 to stimulate P450 activity
allosterically without electron transfer adds further complex-
ity. The hepatic deletion of POR has provided some insight as
to the role the NADH-cytochrome b5 pathway plays in
hepatic drug metabolism in vivo15,16. Drug metabolism by all
microsomal P450s tested was greatly decreased (490%) in
hepatic POR-null microsomes, and in some cases nearly
extinguished. It is thus clear from these studies that the
NADH-b5 pathway cannot support P450 activity to any
signiﬁcant extent in vivo in the absence of POR, a ﬁnding
consistent with the inability of this pathway to support most
P450s in reconstitution studies. There are two possible excep-
tions to this observation that microsomal P450 activity is lost
in the absence of POR: the ﬁnding that approximately 10% of
CYP3A-catalyzed testosterone-6b hydroxylase activity16 and
5% of CYP2E1-catalyzed chlorzoxazone hydroxylase activ-
ity29 remains in POR-null microsomes and hepatocytes. These
observations are consistent with reconstitution and recombi-
nant expression studies which have shown that CYP3A4 and
CYP2E1 are unique in their ability to accept both electrons
from cytochrome b5 and retain activity in the absence of
POR26–28.
Notably, studies with POR-null microsomes do not address
the extent to which cytochrome b5 can donate the secondelectron to P450 catalysis (with the ﬁrst electron coming from
POR), an event that is much more facile than donation of the
ﬁrst electron, and is believed to occur with a greater number of
P450 isoforms. This question is addressed by the deletion of
cytochrome b5 expression, and indeed, the elimination of
cytochrome b5 decreases the activity of a number of micro-
somal P450s by a remarkable 50–90%30,31. Thus, cytochrome
b5, rather than playing a minor and auxiliary role in drug
metabolism, is necessary for maximal activity with a wide
range of P450 isoforms. The stimulation afforded by cyto-
chrome b5 may be either catalytic or allosteric, and likely
depends on the P450 isoform; sorting this out may require the
transgenic expression of redox-inactive forms of cytochrome
b5 in a b5-null animal. Perhaps most surprisingly, the germline
deletion of cytochrome b5 was not embryonic-lethal, as was
anticipated32. Because cytochrome b5 is the electron donor to
two enzymes in the cholesterol synthesis pathway (sterol 4a-
methyl oxidase and lathosterol D5-desaturase), the loss of
cytochrome b5 should have resulted in embryonic lethality due
to the loss of cholesterol synthesis, as seen with germline POR-
null animals. The ability of these animals to survive indicates
that at least one alternative redox protein must be present in
microsomes and is able to substitute for the loss of cyto-
chrome b5. The possibility that this is POR seems unlikely but
cannot be excluded, and a b5-null/hepatic POR null animal
would be particularly interesting in this regard.
The remaining question is to what extent POR donates
electrons to cytochrome b5 in vivo. This can best be tested with
enzymes that utilize cytochrome b5 – and not POR – as a
redox partner, and would include the microsomal fatty acid
desaturases and elongases, and sterol 4a-methyl oxidase and
lathosterol D5-desaturase in sterol synthesis (noted above).
The activity of these enzymes in POR-null liver might be
reduced if POR is a signiﬁcant contributor to the cytochrome
b5 redox steady-state and could be assessed with microsomes
prepared from this tissue. An interesting alternative experi-
ment would be to instead knock out cytochrome b5 reductase
expression, thereby removing the NADH pathway for b5
reduction; remaining activity would presumably be due exclu-
sively to POR-mediated electron transfer to cytochrome b5. As
most of these enzymes demonstrate activity with NADPH in
microsomal preparations, it is likely that POR contributes to
their activity in vivo; the extent of the contribution may
depend on relative NADH and NADPH levels in the cell
and tissue.2.4. 7-Dehydrocholesterol reductase
7-dehydrocholesterol reductase (DHCR7) catalyzes the last
step in cholesterol synthesis. The highly hydrophobic 55 kDa
protein is proposed to contain 6–9 membrane-embedded
segments that bear close similarity to the sterol sensing
domains of HMG-CoA reductase and sterol cleavage activat-
ing protein (SCAP)33. The enzyme has been expressed in yeast
and is active in microsomes in the presence of NADPH33,34;
the enzyme has not been puriﬁed from native or yeast sources
and has not been expressed in a prokaryotic organism,
perhaps due to its highly hydrophobic structure. As a result,
the possibility that accessory microsomal proteins are neces-
sary for activity, including NADPH-dependent electron trans-
fer proteins such as POR, has not been ﬁrmly established.
Figure 1 POR redox partners and pathways. Arrows indicate
electron ﬂow. HMOX, heme oxygenase (2 genes); SQLE, squalene
monooxygenase; CYP, cytochromes P450 (51 microsomal forms);
CYB5, cytochrome b5 (2 genes); MSMO, methylsterol monoox-
ygenase; SC5DL, sterol-C5-desaturase; SCD, stearoyl-CoA desa-
turase (2 genes); ELOVL, fatty acid elongase (7 genes).
New insights into the role of cytochrome P450 reductase 105The absence of a canonical cofactor binding domain raises the
possibility that a redox partner is required for activity and
indeed, Nishino and Ishibashi10 reported evidence that
DHCR7 required POR for activity, based on antibody inhibi-
tion studies and partial puriﬁcation and reconstitution studies.
We11 tested the requirement for POR by using microsomes
from hepatic POR-null mice and were surprised to ﬁnd that
DHCR7 activity was greater in these preparations than in
wild-type microsomes, and correlated with the two-fold higher
levels of DHCR7 protein. Addition of POR to POR-null
microsomes did not augment DHCR7 activity. Antibody to
POR was not inhibitory to DHCR7 in our hands, and
antibodies to each protein did not cross-react. We concluded
that POR was not a required electron donor to 7-dehydro-
cholesterol reductase, and did not augment DHCR7 activity.
Final proof will require, at a minimum, expression of a
functional enzyme in a host system that lacks POR, or
demonstration of activity with the puriﬁed protein.3. Conclusions and perspectives
Cytochrome P450 reductase is a ubiquitous microsomal
electron transfer protein most often associated with drug
and xenobiotic metabolism, but its role in cellular biochem-
istry is much larger than that (summarized in Fig. 1). POR is
essential to steroid hormone synthesis, cholesterol homeostasis
through bile acid synthesis, heme catabolism, and perhaps
most importantly, cholesterol synthesis. Indeed, germline
deletion of POR leads to fetal lethality due to loss of
cholesterol synthesis. POR likely contributes to other redox
pathways through its ability to reduce cytochrome b5, allow-
ing b5-dependent biochemical pathways to draw on both
NADH and NADPH pools for reducing equivalents. These
pathways include fatty acid metabolism (desaturases, elon-
gases) and downstream steps in cholesterol synthesis. Recent
studies with POR-null and cytochrome b5-null tissues haverevealed the presence of additional microsomal redox enzymes
that may substitute for or augment POR and b5-dependent
pathways, and have elucidated the unexpected importance of
cytochrome b5 to P450 biochemistry. Future studies are likely
to be directed at identifying these additional microsomal
electron transfer proteins and their role in microsomal redox
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